The following is a summary of “Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization ...

Two new drugs to treat prostate and liver cancer have been given the green light for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) announced it had recommended the treatments, ...

Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...

Two new medicines have been approved to help treat prostate and liver cancer patients in Scotland. The Scottish Medicines Consortium (SMC) announced it had recommended two treatments for the diseases.

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects ...

Scores of disease and outcome measures decreased substantially within the first 2 weeks, with mean GPPASI reductions of 75.2%. Spesolimab demonstrated rapid and substantial efficacy in treating ...